To better understand the "SaaSpocalyse" fears, I tested how Claude Design and Canva stack up when tasked with designing the ...

Derivative Path, a leading derivatives and risk management platform for financial institutions, today announced the launch of ALM Strategy Builder, a product that gives banks and credit unions the ...

Get lifetime access to PDF Agile for $39.99 and handle editing, converting, signing, compressing, and protecting PDFs on Mac ...

Thank you for your attendance in our earnings call. Before we begin to speak about this quarter, the figures presented and the comparisons with the year 2025 do not include the transaction sector ...

The Allen County Board of Zoning Appeals will hold a public hearing beginning at 5:30 p.m. May 26 for a special use proposal ...

Nu Holdings Ltd. ( NU) Q1 2026 Earnings Call May 14, 2026 6:00 PM EDT ...

Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress.Six ...

Iopofosine I-131 achieved an overall response rate of 83.6% and a major response rate of 61.8% in patients with relapsed or ...

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 ...

Advances Sector-Aligned Growth Strategy While Maintaining Strong Balance Sheet and Positive EBITDA CHELMSFORD, MA / ACCESS ...

Operator: Ladies and gentlemen, thank you for joining, and welcome to the Innate Pharma First Quarter 2026 Business Update and Financial Results.

Earlier today, Celcuity released for the first quarter ended 03/31/2026. The press release can be found on the Investors section of Celcuity's website. Joining me on the call today are Brian F.